Specialty code 174400000X · Mountlake Terrace, WA
NPI
1790869352
Since 2006
Specialty
Specialty code 174400000X
Code 174400000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
6100 219th St SW Ste 480
Mountlake Terrace, WA, 98043
Phone (425) 774-5104
Medicare paid, 2024
$49K
728 services
Medicare patients, 2024
140
Average age 75
Drug cost, 2024
$1.5M
3,617 prescriptions
Company payments, 2025
$322
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Silver was code 99214 (office e&m - established), 429 times for 132 patients. In total Mark A Silver billed 728 services in 10 codes, and Medicare paid $49K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 429 | 132 | $83.59 | $36K |
| 95251 Test - Miscellaneous | Office | 142 | 47 | $26.09 | $3,705 |
| 95250 Test - Miscellaneous | Office | 30 | 16 | $97.25 | $2,918 |
| 99212 Office E&M - Established | Office | 20 | 14 | $30.27 | $605 |
| 99213 Office E&M - Established | Office | 17 | 15 | $46.66 | $793 |
| 99205 Office E&M - New | Office | 15 | 15 | $147.89 | $2,218 |
| 99215 Office E&M - Established | Office | 13 | 13 | $124.19 | $1,615 |
By year: 2022 $76K for 1,232 services; 2023 $63K for 1,146 services; 2024 $49K for 728 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Silver prescribed most often to Medicare patients was Rosuvastatin Calcium, with 420 prescriptions and refills. In total Mark A Silver wrote 3,617 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 420 | 1,173 | 114 | $7,818 |
| Levoxyl Levothyroxine Sodium | 307 | 765 | 78 | $12K |
| Metformin Hcl Er Metformin Hcl | 205 | 571 | 58 | $3,922 |
| Mounjaro Tirzepatide | 160 | 202 | 26 | $213K |
| Jardiance Empagliflozin | 140 | 327 | 36 | $184K |
| Amlodipine Besylate Generic | 123 | 368 | 38 | $1,052 |
| Tresiba Flextouch U-100 Insulin Degludec | 113 | 231 | 32 | $80K |
| Synthroid Levothyroxine Sodium | 108 | 289 | 34 | $13K |
| Ezetimibe Generic | 92 | 267 | 29 | $4,106 |
| Lisinopril Generic | 91 | 226 | 26 | $578 |
| Tresiba Flextouch U-200 Insulin Degludec | 86 | 148 | 20 | $122K |
| Ozempic Semaglutide | 85 | 134 | 15 | $130K |
| Ramipril Generic | 83 | 249 | 24 | $920 |
| Farxiga Dapagliflozin Propanediol | 73 | 177 | 16 | $96K |
| Metformin Hcl Generic | 67 | 193 | 18 | $372 |
Brand drugs: 1,592 claims; generic drugs: 1,870 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark A Silver $322 ($322 in general payments such as food, travel and fees) from 2 companies. The largest payer was Chiesi USA, Inc. with $300.
| Company | Payments | Amount |
|---|---|---|
| Chiesi USA, Inc. | 1 | $300 |
| Insulet Corporation PODD | 1 | $22.41 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.